Tag Archives: disorders

UK authorises gene therapy for blood disorders in world first – Reuters

  1. UK authorises gene therapy for blood disorders in world first Reuters
  2. UK regulators approve medical treatment involving CRISPR gene editing in world first CNN
  3. World’s first CRISPR-based medicine wins approval in U.K. STAT
  4. Vertex and CRISPR Therapeutics Announce Authorization of the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), by the United Kingdom MHRA for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta T Business Wire
  5. The world’s first gene therapy for sickle cell and thalassemia has been approved The Associated Press
  6. View Full Coverage on Google News

Read original article here

Day and night light exposure are associated with psychiatric disorders: an objective light study in >85,000 people – Nature.com

  1. Day and night light exposure are associated with psychiatric disorders: an objective light study in >85,000 people Nature.com
  2. Largest ever study on light exposure proves its impact on mental health Medical Xpress
  3. Ambient greenness, access to local green spaces, and subsequent mental health: a 10-year longitudinal dynamic panel study of 2·3 million adults in Wales The Lancet
  4. Exposure to light at night found to increase risk of depression by 30% New Atlas
  5. ‘Almost like injecting a drug’: Sunlight seems to protect us from depression, anxiety Sydney Morning Herald
  6. View Full Coverage on Google News

Read original article here

Psilocybin Microdosing Promising for Mental Health Disorders – Neuroscience News

  1. Psilocybin Microdosing Promising for Mental Health Disorders Neuroscience News
  2. Small doses of mushrooms can have a beneficial effect on mental disorders, study finds Medical Xpress
  3. Repeated low doses of psilocybin increase resilience to stress, lower compulsive actions, and strengthen cortical connections to the paraventricular thalamic nucleus in rats | Molecular Psychiatry Nature.com
  4. Single-Dose Psilocybin for Treatment-Resistant Major Depression Psychiatric Times
  5. Microdosing: What Is It, and Does It Help Your Mental Health? Men’s Health
  6. View Full Coverage on Google News

Read original article here

Rob McElhenney, 46, diagnosed with ‘host of neurodevelopmental disorders and learning disabilities’ – Fox News

  1. Rob McElhenney, 46, diagnosed with ‘host of neurodevelopmental disorders and learning disabilities’ Fox News
  2. Rob McElhenney Reveals Diagnosis for ‘Neurodevelopmental Disorders and Learning Disabilities’ PEOPLE
  3. Rob McElhenney shares he was diagnosed with neurodevelopmental disorders and learning disabilities at 46 CNN
  4. Rob McElhenney makes shocking revelation about his health: Find out Geo News
  5. ‘Always Sunny’ actor Rob McElhenney reveals ‘host of neurodevelopmental disorders’: ‘You’re not alone’ The Hill
  6. View Full Coverage on Google News

Read original article here

Scientists Reveal New Potential Therapeutic Targets for Mental and Neurological Disorders

Cilia are small, hair-like structures found on the surface of cells in the body. They are known to play important roles in various bodily functions, such as sensing the environment and moving fluids. In the brain, cilia have been found to play a crucial role in the striatum, a region that is involved in movement, motivation, and time perception. Recent research has revealed that cilia in the striatum play a key role in our ability to perceive time,

UCI researchers have discovered the crucial role of cilia in the striatum of the brain in time perception.

A recent study from researchers at the University of California, Irvine found that the removal of cilia from the striatum region of the brain negatively impacted time perception and judgement, opening the possibility for new therapeutic targets for mental and neurological conditions such as schizophrenia, Parkinson’s and Huntington’s diseases,

The study, which was recently published in the journal Molecular Neurobiology, uncovered the first evidence of the important role cilia play in timing-dependent dysfunction.

“Our findings may revolutionize our understanding of brain functions and mental disorders in the context of the critical task performed by these previously unappreciated organelles in the brain’s ‘central clock’ function,” said Amal Alachkar, Ph.D., corresponding author, and professor of teaching in UCI’s Department of Pharmaceutical Sciences. “Our results may open new avenues for effective intervention through cilia-targeted therapies for treatment.”

The striatum is part of the brain’s circuitry that performs central clock processes, essential in controlling executive functions such as motor coordination, learning, planning, and decision-making, as well as working memory and attention. Cilia protrude from the brain cell surfaces like antennae, working as a signaling hub that senses and transmits signals to generate appropriate reactions.

To examine their physiological role, the researchers removed cilia from the striatum in mice using conditional gene manipulation technology. These rodents were not able to learn new motor tasks, showed repetitive motor behavior, and exhibited delays in decision-making. They were also deficient in rapidly recalling information about their location and orientation in space and in their ability to filter irrelevant environmental sensory information. However, the mice maintained habitual or already learned motor skills and long-term memories.

“Successful performance of working memory, attention, decision-making, and executive function requires accurate and precise timing judgment, usually within a millisecond to a minute,” Alachkar said. “When that capacity is impaired, it means losing the ability to quickly adjust behavior in response to changes in external stimuli and failing to sustain appropriate, goal-oriented motor responses. Our ongoing work is aimed at understanding the mechanisms by which cilia regulate time perception and developing targeted therapies to improve behavioral deficits.”

Reference: “Cilia in the Striatum Mediate Timing-Dependent Functions” by Wedad Alhassen, Sammy Alhassen, Jiaqi Chen, Roudabeh Vakil Monfared and Amal Alachkar, 2 November 2022, Molecular Neurobiology.
DOI: 10.1007/s12035-022-03095-9

The study was funded by the National Institutes of Health. 



Read original article here

Can Neuroimaging Reveal the Roots of Psychiatric Disorders? Not Just Yet

Summary: While neuroimaging holds great potential in helping researchers link specific patterns of brain activity to mental health disorders, a new study finds there is still a way to go to effectively link neuroimaging results to specific mental health disorders.

Source: Yale

Neuroimaging technology has been shown to hold great promise in helping clinicians link specific symptoms of mental health disorders to abnormal patterns of brain activity. But a new Yale-led study shows there are still kinks to be ironed out before doctors can translate images of the brain to psychiatric disorders such as post-traumatic stress disorder (PTSD).

Their findings are published Jan. 11 in the American Journal of Psychiatry.

Several years ago, The National Institutes of Mental Health launched a multi-billion-dollar research effort to locate biomarkers of brain activity that point to the biological roots of a host of mental health diseases, which today are typically identified by clinical evaluation of a constellation of often overlapping symptoms reported by patients.

“The idea is to forget classification of disease by symptoms and find underlying biological causes,” said Yale’s Ilan Harpaz-Rotem, professor of psychiatry and psychology and senior author of the study.

For the new study, the Yale-led team attempted to replicate the findings of an earlier nationwide neuroimaging study, in which Emory and Harvard scientists linked clusters of brain activity to a variety of outcomes among patients who had arrived at U.S. emergency departments following traumatic events.

Specifically, when researchers measured patients’ brain activity during the performance of simple tasks — including ones that probe responses to threats and rewards — they detected a cluster of brain activity that showed high reactivity to both threat and reward signals and seemed to predict more severe symptoms of PTSD later on.

While they did identify the different clusters of brain activity observed in the earlier study, they found no association with prospective PTSD symptoms. Image is in the public domain

However, when Yale researchers analyzed similar neuroimaging data collected from recent trauma survivors in Israel, they were not able to replicate these findings. While they did identify the different clusters of brain activity observed in the earlier study, they found no association with prospective PTSD symptoms.

“That is not to say one set of data is right and the other is wrong, just that there is a lot of fundamental work that needs to be done to develop reliable models that could generalize across different studies,” said Yale’s Ziv Ben-Zion, a postdoctoral associate at Yale School of Medicine and the corresponding author of the study.

See also

In fact, Yale researchers are currently working with the investigators of the original Emory-Harvard study to merge datasets “to search for common underlying patterns of brain activity associated with different responses to trauma,” Ben-Zion said.

“It took about 100 years to come up with current classifications of mental illness, but we’ve only been exploring refining psychiatric diagnoses using biomarkers for the last 10 years,” said Harpaz-Rotem. “We still have a long way to go.”

About this neuroimaging and mental health research news

Author: Bess Connolly
Source: Yale
Contact: Bess Connolly – Yale
Image: The image is in the public domain

Original Research: The findings will appear in American Journal of Psychiatry

Read original article here

Could Psilocybin Mushrooms Treat Eating Disorders?

Photo-Illustration: The Cut; Photo: Getty

This article was featured in One Great Story, New York’s reading recommendation newsletter. Sign up here to get it nightly.

The first time Sophia Anderson tripped on psychedelic mushrooms, she was 16 years old. It happened in late 2020, in the coastal jungle near Puerto Vallarta, Mexico, and the whole thing had been her mother’s idea. Under the influence, Anderson felt dazed and oddly at ease — which was disconcerting. For the last few years, her life had revolved around desperately and meticulously maintaining the carefully constructed reality inside her head.

Symptoms of Anderson’s eating disorder began to emerge when she was 14. After making the cut for the dance program at the performing-arts academy she attended in Phoenix, Arizona, Anderson threw herself into training. Over the next couple months, she grew increasingly fixated on her body and developed a pattern of not only restricting foods — first her Halloween-candy haul, then entire food groups — but exercising constantly. Her mother, Jennifer Jacobs, had even found Anderson, her eldest of two daughters, awake in the middle of the night doing leg lifts and sit-ups in her bed. “There was a part of me that felt that being skinnier or smaller would make people like me,” Anderson says. In ten weeks, she shed 20 pounds from her five-foot-seven frame and dropped to 103 pounds. (Both Anderson and Jacobs are pseudonyms.)

Her demeanor and personality changed, too. Anderson stopped socializing and became irritable and unruly, flying into hysteria when anyone interfered with her workouts or suggested that she should eat more. “She was always my sweet, mellow, laid-back little girl, and she just started to be full of rage,” Jacobs says. “I’d never seen her like that.” Eventually, in January 2019, Jacobs and her husband drove Anderson to an eating-disorder treatment center in Tucson — an in-patient clinic, which meant she had to stop attending school. Jacobs had scarcely let her daughter attend sleepovers before that. It was, she recalls, “probably the worst day of my life.”

In less than three months, Anderson had restored 20 pounds of weight. But upon returning home, she resumed old habits, like hiding food she claimed to have eaten. “She would look in the mirror and cry all the time about how fat she was and how she hated everything about the way she looked,” Jacobs says.

While there are FDA-approved medications for treating bulimia nervosa and binge eating disorder, there is nothing for anorexia nervosa — and the disorder has the highest mortality rate of all psychiatric illnesses. In addition, “we have almost nothing to offer in terms of proven psychological treatment,” explains Dr. Allan Kaplan, a senior clinician scientist at the Centre for Addiction and Mental Health in Toronto and a professor at the University of Toronto’s Department of Psychiatry.

While desperately searching online for treatment options, Jacobs stumbled upon a news story about a University of Arizona clinical trial that studied the impact of psilocybin mushrooms, or “magic mushrooms,” on patients with OCD (which Anderson had also been diagnosed with). The study is part of a growing area of mental-health research, which has so far mostly focused on illnesses like PTSD and depression; now, a growing number of researchers are seeing new potential for also helping eating-disorder patients. Jacobs couldn’t shake the idea that maybe the drug could finally jolt Anderson out of the labyrinthian narratives in which she was trapped. Clinical trials, though, require participants to be at least 18 years old, so Jacobs decided to look elsewhere.

That’s how she came across the Buena Vida Psilocybin Retreats in Mexico, where magic mushrooms are illegal for recreational use but permitted for traditional spiritual and ceremonial purposes. She pleaded with the owner, Amanda Schendel, to admit her daughter. Schendel, a white American woman originally from Orange County, California, had spent several years studying plant-based ceremonial healing with medicine people from Ecuador, Colombia, Peru, and Mexico. She herself had previously also struggled with disordered eating for years; with the help of psychedelics, “I’ve come to a place of peace with it,” says Schendel of her relationship with food and her body. She agreed to admit Anderson if Jacobs joined as a chaperone. As with many luxury psychedelic retreats, the plush amenities along with a trained staff (which includes facilitators, a chef, and a medical doctor who screens applicants) came with a hefty price tag: an all-inclusive, seven-day package cost approximately $1,000 per person per day.

Anderson had never heard of psychedelic mushrooms before, but she agreed to go with her mother to Mexico. She was intrigued by the possibility that the drug could improve her OCD symptoms, but her eating disorder was a different story.

For those with disordered eating, surrendering to the possible tearing down of the mental frameworks that govern their symptoms can be challenging, as “there is so much disconnection and dysregulation inside of the body,” says eating-disorder recovery coach and psychedelic guide Francesca Annenberg. Patients may perceive their rigid behaviors (like ignoring natural hunger signals in favor of obsessive calorie counting) as protection from things they fear, be it weight gain or loss of control.

Over the phone, Schendel explained to Anderson what the retreat would entail. “I didn’t really know what the psychedelic was going to do,” says Anderson. What she did know was “I was scared that it would mess up the eating disorder.”

The scientific journal Eating and Weight Disorders — Studies on Anorexia, Bulimia and Obesity published the first quantitative analysis of the psychological effects of psychedelics in eating-disorder sufferers in September 2020. The data “demonstrated overwhelming evidence for improvements in depression and well-being scores following the psychedelic experience,” researchers wrote.

There is no single cause of eating disorders, and illness profiles vary widely, but certain characteristics are common and help explain the diseases’ resistance to treatment. Eating disorders have significant genetic underpinnings, which intertwine with factors like life experiences, personality traits, and sociocultural influences. Clinical psychologist Dr. Adele Lafrance, who is researching the effects of psychedelics in eating-disorder sufferers, notes that many patients have difficulties expressing and modulating emotions; symptoms like restrictive dieting engender a sense of control that helps them regulate emotional stress, which “can lead to ruminative patterns around weight, body image, and calorie counts,” she explains. “In some ways, the eating disorder is an attempt at self-medication,” adds UCSF Benioff Children’s Hospitals pediatrician and psychiatrist Dr. Amanda Downey. By tampering with what the brain perceives as “rewards,” eating disorders rewire behaviors that should be aversive as beneficial actions.

So full recovery, researchers postulate, could require not just changing how patients eat or exercise but how they think.

Psychedelic drugs are known to quiet activity in the brain’s default mode network, a group of interconnected structures involved in various cognitive processing related to introspection and self-reflection. In eating-disorder patients, this network often upholds a negative self-image and encourages repeating maladaptive behaviors around eating, exercising, and weight monitoring. “The disorder hijacks neuronal systems in a pathologic way,” Kaplan explains. “No drug that we have now can break those connections. Psychedelics seem to be able to facilitate that.”

A psychedelic experience that disengages neuronal connections dictating patterns of thought can be a powerful respite for individuals who are, say, stuck in a pattern of obsessing over the appearance of their bodies. Moreover, a trip often heightens a sense of mind-body connection and thus helps patients get back in touch with physiological cues like hunger signals, explains Ben Greenberg, a clinical psychologist. But the impact of mushrooms doesn’t end during the trip itself. It’s in the weeks and months that follow when users examine what happened during the psychedelic experience that lasting effects can take hold. Meg Spriggs, a research scientist at the Imperial College London’s Centre for Psychedelic Research, calls this the post-acute phase: “You have this window of opportunity, after the psychedelic, where the brain is kind of more malleable and more plastic,” and perhaps more able to generate new neuronal connections and thinking patterns.

Still, the research is nascent. A team at UCSF is currently getting regulatory approvals for a new study that could be the first to research the impact of psychedelics on young adults with anorexia nervosa. Downey, the assistant medical director of the UCSF Eating Disorders Program, which is leading the study in conjunction with the UCSF Translational Psychedelic Research Program, explains that because young adults still have ongoing neurodevelopment, it’s important to make sure these drugs are safe and effective for them. Because “side effects and adverse effects are remarkably rare” in psilocybin use, she explains, and because psychedelic research is “slowly starting to make its way into more medically vulnerable populations,” researchers feel hopeful about moving their work into younger adults, an age group with an already high prevalence of disordered eating.

Jacobs and Anderson landed in Puerto Vallarta in November 2020. After a 40-minute shuttle ride, they reached Buena Vida’s luxurious oceanfront property on the lush peninsula of Punta Mita, where amenity-rich resorts dot the beaches. Upon arrival, Jacobs and Anderson attended a welcome orientation, during which staff explained the physiological and neurological effects of the mushrooms, which guests would be experiencing three times during the retreat.

In psychedelic medicine, “set and setting” — the former referring to mind-set and the latter to surroundings — are critical for ensuring a safe context for a productive trip. In the right conditions, brain plasticity can enable a positive impact, Spriggs explains. At Buena Vida, facilitators incorporated music, sound, and prayer into the psilocybin rituals, surrounding Anderson with vibrations to encourage her to enter a ceremonial headspace. According to Schendel, the rituals, coupled with the tranquil natural surroundings and the communal environment, help participants open their minds to the newness and wonder of the hallucinogenic experience — and surrender to the realizations that may present themselves.

The environment “opened my eyes to a more spiritual place,” Anderson says. She sensed the psychedelic cajoling her to loosen her grip, then saw visions in her mind’s eye of tight knots loosening. “I could see it kind of rewiring up there,” Anderson recalls. “Kind of letting go of being scared to, like, be me.”

After each ceremony, facilitators organized participants into small groups to unpack any revelations the trip had occasioned. “I felt so much more at peace,” Anderson says of those first psychedelic experiences. Her guides advised her to make time and space in the following weeks and months to tap back into that feeling, through meditation, journaling, and spending time in nature. After they returned home, Jacobs noticed an improvement in her daughter’s OCD symptoms. Compulsive behaviors didn’t dictate Anderson’s routines as much, and she was becoming more relaxed and independent — learning to drive and spending more time with friends. She also allowed herself to eat more food. “She wasn’t pushing back when we would give her meals. She wasn’t hiding food as much,” says Jacobs. After eating a big meal, though, “I would still feel really guilty about it the next day and I would restrict,” Anderson says. Still, the psychedelic experiences had begun poking holes in the narratives that had come to dictate her self-image. “I don’t think I was as angry with myself. And I wasn’t as angry with my parents. But I still definitely was only partially recovered,” she says. “I didn’t hate how I looked anymore, but I didn’t like how I looked.”

Healing is usually nonlinear, explains Annenberg, who treated her own disordered eating with help from psychedelics. “There are things that can happen months, years down the line that finally click,” she says, noting how deeply ingrained eating disorders often are.

A few months later, Anderson asked her mother if they could go back to Buena Vida. Jacobs, feeling encouraged by her daughter taking the initiative to further her own healing, agreed. Though the retreat was expensive, the price was comparable to a week of inpatient treatment, Jacobs rationalized, which would have cost the family $900 per day out of pocket. They returned to Mexico in April 2021.

For Anderson, this second retreat was even more powerful than the first. Though the setting was the same, her mind-set had shifted. This time, she was actively seeking help.

During one ceremony, the mushrooms encouraged her to “try to be kinder to myself and other people,” she recalls, and to let go of the expectations of others. “If they don’t like me, that’s okay.” The sense of newfound freedom that accompanied this epiphany sparked a song lyric from Taylor Swift to play on a loop in her head like a prophecy: “Sacred new beginnings that became my religion.” To better remember her insights, Anderson described them in a journal afterward: “I wrote that ‘skinny and toned is not necessarily good or perfect.’ That was hard for me to write down, I remember — admitting that,” she says.

But the final ceremony of the retreat was the most transformative one Anderson had yet experienced. It didn’t take long for what she describes as a feeling of empowerment and self-compassion to take over her senses. “I felt beautiful for the first time in forever, and I felt happy with myself,” she says. “Just so purely happy.”

After returning home, Anderson began to devote less attention to what her body looked like. “I realized that that feeling (from the final ceremony) was better than any feeling that the eating disorder had ever given me,” she says.

Looking back, Jacobs believes magic mushrooms gave her daughter a second chance. “It’s literally saved Sophia’s life,” Jacobs says — and Anderson agrees. “I’m not scared to eat anymore. I’m excited when my friends are like, ‘Hey, want to go eat ice cream?’ I eat what I want, and I eat when I feel like eating,” she says. “I want to be strong. I don’t just get the lowest-calorie thing — I get what’s going to support my body.” Her days no longer revolve around exercise and calorie restriction, and that has “made my life more exciting. It’s not all about food anymore.”

Now, nearly two years after her second trip to Mexico, Anderson’s eating- disorder symptoms are mostly gone. “We all have bad body-image days, but it’s so much less often, and I can see through it,” she says. During stressful periods at school, she sometimes takes a microdose (not enough to perceptibly “trip”) of magic mushrooms as a form of maintenance treatment, which Anderson feels may help prevent old symptoms from potentially resurfacing. As Greenberg explains, psychedelic healing doesn’t erase the impact of trauma, and “trying to persist in the illusion that ‘I’m completely over this by now’” can be dangerous territory. “Oftentimes, with eating disorders especially, it’s a lot more about remission and maintenance,” he adds.

While psychedelics look like one of the most hopeful interventions in the offing for those struggling with disordered eating and unhealthy body image, Kaplan of the Centre for Addiction and Mental Health cautions it’s much too early to celebrate. But he is hopeful. “Based on the neurobiology of anorexia, and how we know psychedelics work, there seems to be a reason to believe that this could work.” As Downey points out, psilocybin acts on the 5-HT2A serotonin receptor, which is “thought to be highly variable or mutated in anorexia nervosa.”

It’s critical that research proving safety and efficacy in younger patients gets underway soon, Downey adds. “The longer patients go untreated, the longer they stay static, the worse the chance of recovery is down the line,” she explains.

By relying on currently legal and available treatments for the illness, many eating-disorder patients will never fully recover. Over a 20-year period, only 46 percent of people with anorexia will overcome the disorder and go on to lead a life with normal eating behaviors. Another third may experience a reasonable quality of life but will continue to exhibit symptoms, Kaplan says. The remaining 20 percent will suffer from what he calls severe and enduring anorexia nervosa — the same group, he says, that psychedelic treatment could help the most.

Considering the inadequacy of available treatments for anorexia nervosa patients and the illness’s high mortality rate, there is little to lose. “Of all the disorders in psychiatry, this is the one disorder where we really need to try something out of the box,” Kaplan says.

Anderson is now in her senior year of high school. She’s applying for colleges and plans to elect psychology as her major. “When people ask me what I want to do career-wise, I tell them I would love to do psilocybin-assisted therapy,” she says. “Mushrooms changed my life, and I’m forever grateful for that.”

Read original article here

Child Body Weight Has Limited Effects on Mood and Behavioral Disorders

Summary: Despite common belief, a new study reveals a child’s body weight has little impact on mood or behavioral disorders.

Source: University of Bristol

Childhood body mass index is unlikely to have a big impact on children’s mood or behavioral disorders, according to a study led by the University of Bristol and published today in eLife.

The results suggest that some previous studies, which have shown a strong link between childhood obesity and mental health, may not have fully accounted for family genetics and environmental factors.

Children with obesity are more likely to be diagnosed with depression, anxiety, or attention-deficit hyperactivity disorder (ADHD). But the nature of the relationship between obesity and these mental health conditions is not clear.

Obesity might contribute to mental health symptoms, or vice versa. Alternatively, a child’s environment might contribute to both obesity and mood and behavioral disorders.

“We need to better understand the relationship between childhood obesity and mental health,” said lead author Dr. Amanda Hughes, Senior Research Associate in Epidemiology in the Bristol Medical School: Population Health Sciences (PHS) at the University of Bristol.

“This requires teasing apart the contributions of child and parent genetics and the environmental factors affecting the whole family.”

Dr. Hughes and colleagues examined genetic and mental health data from 41,000 eight-year-old children and their parents from the Norwegian Mother, Father, and Child Cohort Study and Medical Birth Registry of Norway.

They assessed the relationship between children’s body mass index (BMI)—a ratio of weight and height—and symptoms of depression, anxiety and ADHD. To help separate the effects of the children’s genetics from the influence of other factors that affect the whole family, they also accounted for parental genetics and BMI.

The analysis found a minimal effect of a child’s own BMI on their anxiety symptoms. There was also conflicting evidence about whether a child’s BMI influenced their depressive or ADHD symptoms. This suggests that policies aiming to reduce childhood obesity are unlikely to have a big impact on the prevalence of these conditions.

The results suggest that some previous studies, which have shown a strong link between childhood obesity and mental health, may not have fully accounted for family genetics and environmental factors. Image is in the public domain

“At least for this age group, the impact of a child’s own BMI appears small. For older children and adolescents, it could be more important,” said Neil Davies, Professor at University College London (UCL).

When they looked at the effect of the parents’ BMI on the children’s mental health, the team found little evidence that the parents’ BMI affected children’s ADHD or anxiety symptoms. The data suggested that having a mother with a higher BMI might be linked with depressive symptoms in children, but there was little evidence of any link between the child’s mental health and the father’s BMI.

“Overall, the influence of a parent’s BMI on a child’s mental health seems to be limited. As a result, interventions to reduce parents’ BMIs are unlikely to have widespread benefits to children’s mental health,” added Alexandra Havdahl, Research Professor at the Norwegian Institute of Public Health.

“Our results suggest that interventions designed to reduce child obesity are unlikely to make big improvements in child mental health. On the other hand, policies which target social and environmental factors linked to higher body weights, and which target poor child mental health directly, may be more beneficial,” Hughes concluded.

About this neurodevelopment, weight, and behavior research news

Author: Press Office
Source: University of Bristol
Contact: Press Office – University of Bristol
Image: The image is in the public domain

See also

Original Research: Open access.
“Body mass index and childhood symptoms of depression, anxiety, and attention-deficit hyperactivity disorder: A within-family Mendelian randomization study” by Amanda M Hughes et al. eLife


Abstract

Body mass index and childhood symptoms of depression, anxiety, and attention-deficit hyperactivity disorder: A within-family Mendelian randomization study

Background:

Higher BMI in childhood is associated with emotional and behavioural problems, but these associations may not be causal. Results of previous genetic studies imply causal effects but may reflect influence of demography and the family environment.

Methods:

This study used data on 40,949 8-year-old children and their parents from the Norwegian Mother, Father and Child Cohort Study (MoBa) and Medical Birth Registry of Norway (MBRN). We investigated the impact of BMI on symptoms of depression, anxiety, and attention-deficit hyperactivity disorder (ADHD) at age 8. We applied within-family Mendelian randomization, which accounts for familial effects by controlling for parental genotype.

Results:

Within-family Mendelian randomization estimates using genetic variants associated with BMI in adults suggested that a child’s own BMI increased their depressive symptoms (per 5 kg/m2 increase in BMI, beta = 0.26 S.D., CI = −0.01,0.52, p=0.06) and ADHD symptoms (beta = 0.38 S.D., CI = 0.09,0.63, p=0.009). These estimates also suggested maternal BMI, or related factors, may independently affect a child’s depressive symptoms (per 5 kg/m2 increase in maternal BMI, beta = 0.11 S.D., CI:0.02,0.09, p=0.01). However, within-family Mendelian randomization using genetic variants associated with retrospectively-reported childhood body size did not support an impact of BMI on these outcomes. There was little evidence from any estimate that the parents’ BMI affected the child’s ADHD symptoms, or that the child’s or parents’ BMI affected the child’s anxiety symptoms.

Conclusions:

We found inconsistent evidence that a child’s BMI affected their depressive and ADHD symptoms, and little evidence that a child’s BMI affected their anxiety symptoms. There was limited evidence of an influence of parents’ BMI. Genetic studies in samples of unrelated individuals, or using genetic variants associated with adult BMI, may have overestimated the causal effects of a child’s own BMI.

Funding:

This research was funded by the Health Foundation. It is part of the HARVEST collaboration, supported by the Research Council of Norway. Individual co-author funding: the European Research Council, the South-Eastern Norway Regional Health Authority, the Research Council of Norway, Helse Vest, the Novo Nordisk Foundation, the University of Bergen, the South-Eastern Norway Regional Health Authority, the Trond Mohn Foundation, the Western Norway Regional Health Authority, the Norwegian Diabetes Association, the UK Medical Research Council. The Medical Research Council (MRC) and the University of Bristol support the MRC Integrative Epidemiology Unit.

Read original article here

Antidepressant Use and Infection During Pregnancy Linked to Neurodevelopmental Disorders

Summary: A combination of antidepression use and infections that lead to inflammation during pregnancy increase the risk of neurodevelopmental disorders including autism in children, a new study reports.

Source: University of Virginia

Antidepressant use during pregnancy may combine with inflammation to heighten the risk of lifelong neurodevelopmental changes in babies’ brains, such as those linked to autism, new research from the University of Virginia School of Medicine suggests.

A team of UVA neuroscientists found that commonly used antidepressants known as selective serotonin reuptake inhibitors (SSRIs) can interact powerfully with inflammation in the mother’s body from infections or other sources. In lab mice, this interaction caused harmful changes in the placenta and the decidua—the direct connection between mother and child—and affected the developing brain.

“Our findings suggest that [SSRIs] can have deleterious consequences when mixed with infection, inflammation, etc.,” said senior researcher John Lukens, Ph.D., of the UVA Department of Neuroscience and its Center for Brain Immunology and Glia (BIG), as well as the UVA Brain Institute.

“Our results might help to explain the rise in autism prevalence over the last 20 years, as this time coincides with the rollout of widespread SSRI usage in the developing world.”

SSRIs During Pregnancy

SSRIs are commonly used during pregnancy, being prescribed to 80% of pregnant women who need depression medication. The drugs are widely considered a safe option for managing depression in pregnant women, though there has been some evidence that they can increase the chances of premature delivery as well as up the risk of neurological issues and other health problems in children.

Lukens and his collaborators found that SSRIs can interact with the mother’s immune system to produce a strong inflammatory reaction at the “maternal-fetal interface,” the physical connection between mother and offspring during pregnancy.

The offspring of mothers exposed to inflammation later showed sex-based behavioral changes like the behaviors seen in people with autism, such as diminished communication and decreased interest in social interactions. Such mouse models are widely used as an important autism research tool.

“We identified inflammatory signatures in the placenta that correlated with neurologic changes in the adult offspring of mothers that encountered an immune challenge during pregnancy,” said researcher Kristine Zengeler, the first author of a new scientific paper outlining the findings.

“These signatures could be used to help identify biomarkers and druggable targets to help mitigate neurodevelopmental consequences of prenatal environmental stressors, like an immune response.”

Prior research has shown that infections, autoimmune disorders and other conditions that alter a mother’s immune state during pregnancy can affect neurodevelopment. SSRIs, the UVA researchers believe, may be interacting with that inflammation and amplifying it, leading to permanent brain changes.

The results make sense, the researchers say, because of how SSRIs alter serotonin in the body. Serotonin is an important mood regulator—it’s often thought of as a “feel good” chemical in the brain—but it’s also a vital regulator of the body’s immune response. Developing infants receive serotonin only from their mothers via the placenta in the early stages of pregnancy, so disrupting serotonin levels in mom may have consequences for baby as well.

SSRIs are commonly used during pregnancy, being prescribed to 80% of pregnant women who need depression medication. Image is in the public domain

The researchers found that inflammation alone and in combination with SSRIs altered serotonin levels in the placenta, yet in opposite directions. “We found that mothers who encountered an immune challenge during pregnancy showed a totally different signature in the placenta when they were on SSRIs compared to mothers that were not on SSRIs,” Zengeler said.

“This highlights the importance of considering the entire prenatal environment, as drugs designed to dampen inflammation may lead to unanticipated consequences on the baby if they are combined with other modulators, such as SSRIs.”

The researchers noted that SSRIs are important tools for managing depression and emphasized that pregnant women should not stop taking them without consulting their doctors. Instead, the scientists are calling for additional studies, eventually in human subjects, to determine how the drugs may affect mother and child and to better understand the interactions of SSRIs and inflammation.

“Untreated maternal stress, depression and anxiety can all on their own perturb offspring neurodevelopment, contributing to adverse behavioral and cognitive outcomes,” the researchers write. “It will therefore be of utmost importance to consider both the relative benefits and potential consequences of SSRIs as a therapeutic option during pregnancy.”

The researchers have published their findings in the journal Brain, Behavior, and Immunity. Lukens’ lab also recently made a discovery that could hold the key for boosting the brain’s ability to fight Alzheimer’s disease and multiple sclerosis.

About this pregnancy and neurodevelopment research news

Author: Press Office
Source: University of Virginia
Contact: Press Office – University of Virginia
Image: The image is in the public domain

See also

Original Research: Open access.
“SSRI treatment modifies the effects of maternal inflammation on in utero physiology and offspring neurobiology” by Kristine E. Zengeler et al. Brain, Behavior, and Immunology


Abstract

SSRI treatment modifies the effects of maternal inflammation on in utero physiology and offspring neurobiology

Perturbations to the in utero environment can dramatically change the trajectory of offspring neurodevelopment. Insults commonly encountered in modern human life such as infection, toxins, high-fat diet, prescription medications, and others are increasingly linked to behavioral alterations in prenatally-exposed offspring.

While appreciation is expanding for the potential consequence that these triggers can have on embryo development, there is a paucity of information concerning how the crucial maternal-fetal interface (MFI) responds to these various insults and how it may relate to changes in offspring neurodevelopment.

Here, we found that the MFI responds both to an inflammatory state and altered serotonergic tone in pregnant mice. Maternal immune activation (MIA) triggered an acute inflammatory response in the MFI dominated by interferon signaling that came at the expense of ordinary development-related transcriptional programs.

The major MFI compartments, the decidua and the placenta, each responded in distinct manners to MIA. MFIs exposed to MIA were also found to have disrupted sex-specific gene expression and heightened serotonin levels. We found that offspring exposed to MIA had sex-biased behavioral changes and that microglia were not transcriptionally impacted.

Moreover, the combination of maternal inflammation in the presence of pharmacologic inhibition of serotonin reuptake further transformed MFI physiology and offspring neurobiology, impacting immune and serotonin signaling pathways alike.

In all, these findings highlight the complexities of evaluating diverse environmental impacts on placental physiology and neurodevelopment.

Read original article here

New Study Maps the Development of the 20 Most Common Psychiatric Disorders

Summary: 47% of patients with a mental health disorder receive a different diagnosis within the first ten years of receiving their initial diagnosis.

Source: University of Copenhagen

“Let’s see how things go.”

So psychiatrists often say to one another after a patient has been diagnosed with the first disorder – not because the diagnosis is not correct, but because psychiatrists know that psychiatric diagnoses have a tendency to change over the years.

In fact, 47 percent of psychiatric patients are diagnosed with a different diagnosis within 10 years of receiving their first diagnosis.

This is the result of a new study mapping the diagnostic development of more than 180,000 psychiatric patients in Denmark.

One of the researchers behind the study is Clinical Research Associate Professor at the Department of Clinical Medicine Anders Jørgensen. He is not surprised by the results of the study.

“Mental disorders are dynamic. They change over the course of a life. Therefore, I am not surprised by the relatively great diagnostic development in these patients,” says Anders Jørgensen.

The study shows which development is probable and which is improbable for the 20 most common mental diagnoses. The most uncertain, i.e., the ones that are most likely to change, include the diagnoses acute psychosis, addiction and depression.

The most certain, i.e. the ones that are least likely to change, include the diagnoses functional disabilities, which are long-term physical disabilities with no physical cause, eating disorders and sexual disorders such as reduced sexual interest or erectile dysfunction with no physical cause.

The study is useful from the moment a patient is diagnosed with his or her first disorder, as it enables doctors to look up the 10-year diagnostic development of other patients.

“Doctors wanting to plan the right course of treatment and be able to tell patients what they can expect need these figures. Ultimately, we hope it can help improve treatment and ensure evidence-based follow-up. The more you know about the probable course of illness, the better the treatment is likely to be,” says Anders Jørgensen.

The study is limited to patients treated in the psychiatric healthcare system. This means that the people who go to their GP and are referred to a psychologist are not included in the study.

“We only look at people who have been diagnosed in psychiatric hospitals and who typically experience more severe courses of illness than those who make an appointment with their GP,” says Anders Jørgensen.

Depression is one of the most uncertain diagnoses

Among the three most common diagnoses analysed in the study, patients diagnosed with a single episode of depression have the highest risk of being diagnosed with a new disorder within 10 years.

“According to the study, patients with this diagnosis have a 60-percent chance of being diagnosed with a new disorder within 10 years,” says Associate Professor Terese Sara Høj Jørgensen from the Section of Social Medicine at the Department of Public Health.

But numbers can be deceiving. Because the majority (20 percent) of those diagnosed with a single episode of depression is subsequently diagnosed with periodic depression, which is the name for recurring depressions.

“It is not surprising that a single episode of depression can develop into recurring depressions,” says Anders Jørgensen.

The study shows which development is probable and which is improbable for the 20 most common mental diagnoses. Image is in the public domain

Next to periodic depression, personality disorder and stress reaction disorders are the diagnoses most likely to follow a depression diagnosis. A stress reaction disorder is when a major incident such as divorce or death causes the patient to develop a mental disorder resembling stress or depression. 

Anders Jørgensen hopes the new data can help improve treatment for people who suffer a depression.

“Unlike patients who experience their first psychosis, we currently have no uniform treatment option for patients who experience their first depression. We may look into developing such an option, and our figures can support the development of effective treatment,” says Anders Jørgensen.

What did the study entail?

Using Danish register data, the researchers identified psychiatric patients aged 18 years or more diagnosed with one of the 20 most common mental disorders. This gave them a group of 184,949 individuals.

The researchers looked at how the patients’ diagnoses have change since the first diagnosis was given. They used so-called sequence analysis to analyse the development.

Typical development for the three most common diagnoses analysed in the study

Depression: 60 percent of those diagnosed with a single depressive episode are diagnosed with a new disorder within 10 years. 20 percent develop periodic depression, 10 percent a stress disorder and six percent a personality disorder.

See also

Addiction: 52 percent are diagnosed with a new disorder within 10 years. Eight percent develop a stress disorder, five percent a personality disorder and five percent schizophrenia. The category includes all addiction diagnoses such as alcohol, opioid, cannabis etc. Some forms of addiction are more uncertain than others.

Stress reaction disorder: 36 percent are diagnosed with a new disorder within 10 years. Eight percent develop a single depressive episode, seven percent a personality disorder and six percent periodic depression.

About this mental health research news

Author: Liva Polack
Source: University of Copenhagen
Contact: Liva Polack – University of Copenhagen
Image: The image is in the public domain

Original Research: Closed access.
“Mapping diagnostic trajectories from the first hospital diagnosis of a psychiatric disorder: a Danish nationwide cohort study using sequence analysis” by Anders Jørgensen et al. Lancet Psychiatry


Abstract

Mapping diagnostic trajectories from the first hospital diagnosis of a psychiatric disorder: a Danish nationwide cohort study using sequence analysis

Background

A key clinical problem in psychiatry is predicting the diagnostic future of patients presenting with psychopathology for the first time. The objective of this study was to establish a comprehensive map of subsequent diagnoses after a first psychiatric hospital diagnosis.

Methods

Through the Danish National Patient Registry, we identified patients aged 18 years or older with an inpatient or outpatient psychiatric hospital contact and who had received one of the 20 most common first-time psychiatric diagnoses (defined at the ICD-10 two-cipher level, F00–F99) between Jan 1, 1995, and Dec 31, 2008. For each first-time diagnosis, the 20 most frequent subsequent psychiatric diagnoses (F00–F99), and death, occurring during 10 years of follow-up were identified as outcomes. To assess diagnostic stability, we used social sequence analyses, assigning a subsequent diagnosis to each state with a length of 6 months following each first-time diagnosis. The subsequent diagnosis was defined as the last diagnosis given within each 6-month period. We calculated the normalised entropy of each sequence to show the uncertainty of predicting the states in a given sequence. Cox proportional hazards models were used to assess the risk of receiving a subsequent diagnosis (at the one-cipher level, F0–F9) after each first-time diagnosis.

Findings

The cohort consisted of 184 949 adult patients (77 129 [41·7%] men and 107 820 [58·3%] women, mean age 42·5 years [SD 18·5; range 18 to >100). Ethnicity data were not recorded. Over 10 years of follow-up, 86 804 (46·9%) patients had at least one subsequent diagnosis that differed from their first-time diagnosis. Measured by mean normalised entropy values, persistent delusional disorders (ICD-10 code F22), mental and behavioural disorders due to multiple drug use and use of other psychoactive substances (F19), and acute and transient psychotic disorders (F23) had the highest diagnostic variability, whereas eating disorders (F50) and non-organic sexual dysfunction (F52) had the lowest. The risk of receiving a subsequent diagnosis with a psychiatric disorder from an ICD-10 group different from that of the first-time diagnosis varied substantially among first-time diagnoses.

Interpretation

These data provide detailed information on possible diagnostic outcomes after a first-time presentation in a psychiatric hospital. This information could help clinicians to plan relevant follow-up and inform patients and families on the degree of diagnostic uncertainty associated with receiving a first psychiatric hospital diagnosis, as well as likely and unlikely trajectories of diagnostic progression.

Funding

Mental Health Services, Capital region of Denmark.

Translation

For the Danish translation of the abstract see Supplementary Materials section.

Read original article here